DADC
RXRX icon

D.A. Davidson & Co’s Recursion Pharmaceuticals RXRX Stock Holding History

D.A. Davidson & Co’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$350 – 1480
2024
Q4 		$350 Hold
2
– – ﹤0.01% 1417
2024
Q3 		$390 Hold
2
– – ﹤0.01% 1376
2024
Q2 		$660 Sell
2
-1
-33% -$9 ﹤0.01% 1364
2024
Q1 		$1.28K Buy
+3
New +$33 ﹤0.01% 1374

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

D.A. Davidson & Co's RXRX Position: Q2 2025 in Review

D.A. Davidson & Co sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 107,432 shares — an estimated $568K sold.

D.A. Davidson & Co first reported a position in RXRX in Q1 2024 and held it in 5 quarters. The position peaked at $807K in Q2 2024. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • D.A. Davidson & Co reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • D.A. Davidson & Co sold 107,432 Recursion Pharmaceuticals shares in Q2 2025, an estimated $568K.
  • D.A. Davidson & Co first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • D.A. Davidson & Co's Recursion Pharmaceuticals position peaked at $807K in Q2 2024.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on D.A. Davidson & Co's 13F filing for Q2 2025, filed 30 Jul 2025.